Sign In
Buy ZYNE
$1.30
+0 (+0%)
At Close: Jan 09, 2024
22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a genetic disorder caused by a chromosome 22 deletion, presenting symptoms like heart defects, immune deficiencies, and developmental del
Dublin, July 31, 2024 (GLOBE NEWSWIRE) -- The "Fragile X Syndrome - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insi
Why Shares of Harmony Bioscience Are Falling on Friday
12:52pm, Friday, 13'th Oct 2023
Harmony has already gotten approval for the drug to treat adults with excessive daytime sleepiness who have narcolepsy. Harmony's second-quarter revenue was up 25%, year over year.
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
08:00am, Wednesday, 11'th Oct 2023
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zyge
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
04:05pm, Wednesday, 04'th Oct 2023
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychia
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
09:00am, Friday, 29'th Sep 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychi
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
08:00am, Wednesday, 27'th Sep 2023
PLYMOUTH MEETING, Pa. , Sept. 27, 2023 /PRNewswire/ -- In connection with the previously announced merger agreement, Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), today announced th
Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatmen
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Phar
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Phar
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
01:52pm, Monday, 14'th Aug 2023
In a stunning turn of the tables, beleaguered cannabinoid therapeutics developer Zynerba Pharmaceuticals (NASDAQ: ZYNE ) skyrocketed on Monday following an announcement early this morning of a buyout.
Zynerba Pharma stock rockets on premium priced Harmony deal
09:29am, Monday, 14'th Aug 2023
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock rocketed three-times higher as investors are set to pocket a bumper payday as Harmony Biosciences (NASDAQ:HRMY) agreed to buy the cannabinoid therapies
Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million
09:18am, Monday, 14'th Aug 2023
Shares of Zynerba Pharmaceuticals Inc. ZYNE, +0.89% jumped 300% premarket on Monday after Harmony Biosciences Holdings Inc. HRMY, -0.47% said it would acquire the cannabinoid therapy company in a deal
ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders
08:45am, Monday, 14'th Aug 2023
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) to Harmony Biosciences Holdings, Inc. is fai
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
07:30am, Monday, 14'th Aug 2023
PLYMOUTH MEETING, Pa. and DEVON, Pa.
